The present invention covers 2-methyl-aza-quinazoline compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients
The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.
Thiophene Derivatives, Their Manufacture and Use as Pharmaceutical Agents
申请人:Fertig Georg
公开号:US20070232602A1
公开(公告)日:2007-10-04
Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
Thiophene derivatives, their manufacture and use as pharmaceutical agents
申请人:Hoffmann-La Roche Inc.
公开号:US07396944B2
公开(公告)日:2008-07-08
Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
[EN] SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS<br/>[FR] AGENTS DE DÉGRADATION DE PROTÉINE SOS1, COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI, ET LEURS APPLICATIONS THÉRAPEUTIQUES
申请人:BIOTHERYX INC
公开号:WO2022061348A1
公开(公告)日:2022-03-24
Provided herein are SOS1 protein degraders, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an SOS1-mediated disorder, disease, or condition.